ProCE Banner Activity

Treatment-Resistant Bipolar Disorders

Slideset

This presentation on treatment-resistant bipolar disorders reviews treatments effective in resistant mania; comorbidities in bipolar disorder; innovative treatment options; and efficacy of various treatments in bipolar disorder.

Released: March 22, 2022

Expiration: March 21, 2023

No longer available for credit.

Share

Faculty

Roger McIntyre

Roger McIntyre, MD, FRCPC

Professor of Psychiatry and Pharmacology
University of Toronto, Canada
Chairman and Executive Director, Brain and Cognition Discovery Foundation
Toronto, Canada
Board Chair, Depression and Bipolar Support Alliance
Board of Directors
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Independent Educational Activity

Faculty Disclosure

Primary Author

Roger McIntyre, MD, FRCPC

Professor of Psychiatry and Pharmacology
University of Toronto, Canada
Chairman and Executive Director, Brain and Cognition Discovery Foundation
Toronto, Canada
Board Chair, Depression and Bipolar Support Alliance
Board of Directors
Chicago, Illinois

Roger McIntyre, MD, FRCPC, has disclosed that he has received speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Eisai, Intra-Cellular, Abbvie. Dr. Roger McIntyre is CEO of Braxia Scientific Corp.